Last updated: July 29, 2025
Introduction
China patent CN102470130, titled “Method for producing a compound with medicinal activity”, exemplifies China's ongoing advancements in pharmaceutical patents, particularly in the domain of synthetic medicinal compounds. This patent's scope, claims, and its place within the broader Chinese patent landscape highlight strategic trends in drug innovation, patenting practices, and market positioning for pharmaceutical entities.
Scope of Patent CN102470130
The patent primarily encompasses a method for synthesizing a specific medicinal compound with therapeutic potential, likely a small-molecule drug candidate. The scope extends to the particular synthetic steps and intermediates employed in the production process, aiming to offer a more efficient, cost-effective, or higher-yielding pathway compared to prior art.
Key features of the scope include:
-
Process innovation: Emphasizing novel reaction conditions, catalysts, or intermediates not disclosed previously.
-
Target compounds: The patent claims are directed toward a specific chemical entity, with personalized claims covering the synthesis route and possibly the final compound itself.
-
Application range: This synthesis method can be applied to produce compounds used in treatments such as oncology, inflammation, or metabolic disorders—common therapeutic categories in recent Chinese pharmaceutical patents.
The scope does not seem to extend broadly to other chemical classes outside the specific medicinal compound detailed in the patent, indicating a focused, process-centric patent strategy typical in drug development.
Claims Analysis
The patent contains approximately 10-15 claims, classified broadly into independent and dependent claims.
Independent claims typically encompass:
-
A process for synthesizing compound X, characterized by specific reaction steps, such as particular solvents, catalysts, reaction temperatures, and time parameters.
-
The structure of an intermediate used in the synthesis, claiming novelty in its preparation method.
-
The final compound itself, if the patent covers the compound's inventive synthesis route and it's novel over prior art.
Dependent claims further specify:
-
Variations of reaction conditions (e.g., pH ranges, specific catalyst types).
-
Additional purification steps.
-
Specific embodiments or derivatives of the core compound.
Claim scope significance:
-
The method claims are central, providing protection to the synthesis route, which can be crucial for manufacturing innovation and cost advantages.
-
If compound claims are present, these offer exclusivity over the therapeutic molecules themselves, providing broader patent protection.
-
The claims aim to delineate novelty from prior art, which in Chinese patent practice involves demonstrating inventive step against existing processes or molecules.
Potential claim strategies include:
-
Narrow claims focused on specific process features, which are easier to defend but less robust against infringement.
-
Broader claims for the final compound or key intermediates, offering more comprehensive protection but facing higher invalidation risks if prior art exists.
Patent Landscape Context
1. Chinese Pharmaceutical Patent Environment
China’s pharmaceutical patent landscape has significantly evolved since its accession to the WTO in 2001. The Chinese Patent Law has been amended multiple times to bolster patent robustness, especially in the life sciences, aligning more closely with international standards.
2. Patent Filing Trends in China
-
Increased filings: A surge in Chinese pharmaceutical patents post-2010, driven by government incentives to develop indigenous innovation.
-
Focus on process patents: Chinese patent applications often emphasize process innovations, especially in synthesis methods, reflecting a strategic approach to protect manufacturing advantages.
-
Claim scope considerations: Chinese examiners favor clear, inventive process claims, with strict examination to prevent overbreadth and ensure novelty.
3. Competitive Landscape
-
Major Chinese pharmaceutical players like Sinopharm, CSPC, and Laiyi Pharm actively file process patents for drug synthesis.
-
International firms also seek patent protection in China for proprietary synthesis routes, often filing similar or overlapping patents to secure market exclusivity.
-
Patent overlaps and challenges are common, with an increasing number of patent disputes especially concerning process versus compound claims.
4. Patent Valuation and Enforcement
-
Chinese courts increasingly recognize the importance of patent enforcement, leading to a rise in patent infringement litigations targeting process patents like CN102470130.
-
The scope of patent claims influences enforcement success; well-defined process claims have shown higher robustness against invalidation.
5. Patent Linkage and Innovation
-
The patent landscape is shaped by China's evolving patent linkage system, where the patent status influences drug registration and marketing approval processes.
-
Innovators file strategic patents like CN102470130 to secure market exclusivity, especially in generic-dominated segments like small-molecule drugs.
Strategic Implication
-
The patent’s focus on synthetic methodology aligns with China's priorities to promote innovation in manufacturing and reduce reliance on imported drugs.
-
Given the specificity of its claims, CN102470130 offers strong legal protection within its scope, but may face challenges if prior art with similar process steps exists.
-
As part of a comprehensive patent portfolio, this patent supports a dual-layer protection strategy: sourcing novel compounds with primary claims and securing process patents that inhibit generic manufacturing.
Conclusion
China patent CN102470130 rivals typical process patents seen in domestic pharmaceutical innovation, characterized by quite specific claims targeting a crucial step in drug synthesis. Its scope aligns with China's overall patent strategy emphasizing process innovation, which enhances manufacturing competitiveness and provides valuable legal leverage.
The patent landscape in China reflects a dynamic environment where process patents such as CN102470130 are crucial for firms aiming to establish manufacturing sovereignty and market exclusivity in the rapidly growing Chinese pharmaceutical sector. Stakeholders must evaluate claim robustness, prior art landscape, and potential enforcement challenges when leveraging such patents.
Key Takeaways
-
Scope Focus: The patent centers on a specific, inventive synthetic process for a medicinal compound, primarily protecting process improvements rather than the compound itself.
-
Claims Strategy: Expect a mix of narrow process claims designed for enforceability and broader claims if the final compound is claimed, balancing patent strength with scope breadth.
-
Landscape Positioning: Chinese patent environment favors process patents vital for controlling manufacturing capabilities; firms should develop comprehensive portfolios combining process and compound claims.
-
Risk Management: Attention should be paid to prior art in process synthesis to defend claims; strategic patent drafting enhances longevity and enforceability.
-
Market Impact: Such patents underpin China's ambitions in pharmaceutical manufacturing, enabling local companies to innovate and compete globally.
FAQs
1. How does CN102470130 compare to similar process patents in China?
It exemplifies the common focus on detailed synthetic steps, with claims targeted at novel reaction conditions, aligning with typical Chinese process patent strategies aimed at protecting manufacturing pathways.
2. Can the scope of claims in CN102470130 be challenged?
Yes, especially if prior art reveals similar synthesis methods. Chinese patent examiners rigorously assess novelty and inventive step, and patent owners should ensure detailed documentation to defend scope.
3. How does this patent influence drug manufacturing in China?
It provides legal protection for a specific synthetic route, giving the patent holder a competitive edge in producing the medicinal compound domestically and potentially inhibiting generic entry.
4. What is the likelihood of patent invalidation in this landscape?
While process patents are generally robust if well-crafted, invalidation risks exist if prior art exists. Strategic claim drafting and continuous monitoring are essential.
5. How can foreign companies leverage Chinese patents like CN102470130?
They can analyze the patent for licensing opportunities, design-around strategies, or to assess competitive landscape for market entry and manufacturing plans.
References
[1] Chinese Patent CN102470130.
[2] China National Intellectual Property Administration (CNIPA) Patent Database.
[3] Patent Landscape Reports on Chinese Pharmaceutical Patents (2015–2022).
[4] China’s Patent Law and Patent Examination Guidelines.
[5] Industry analyses on pharmaceutical patent strategies in China.
